Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
85% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. GHDX: No Debt )
GHDX' s 10-Year Cash to Debt Range
Min: 4.9   Max: No Debt
Current: No Debt

Equity to Asset 0.81
GHDX's Equity to Asset is ranked higher than
83% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. GHDX: 0.81 )
GHDX' s 10-Year Equity to Asset Range
Min: -3.56   Max: 0.89
Current: 0.81

-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
96% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. GHDX: No Debt )
GHDX' s 10-Year Interest Coverage Range
Min: 80.08   Max: 9999.99
Current: No Debt

80.08
9999.99
F-Score: 4
Z-Score: 18.94
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -7.29
GHDX's Operating margin (%) is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. GHDX: -7.29 )
GHDX' s 10-Year Operating margin (%) Range
Min: -12348   Max: 4.01
Current: -7.29

-12348
4.01
Net-margin (%) -7.69
GHDX's Net-margin (%) is ranked higher than
63% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. GHDX: -7.69 )
GHDX' s 10-Year Net-margin (%) Range
Min: -12200   Max: 3.81
Current: -7.69

-12200
3.81
ROE (%) -14.69
GHDX's ROE (%) is ranked higher than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. GHDX: -14.69 )
GHDX' s 10-Year ROE (%) Range
Min: -1865.06   Max: 7.79
Current: -14.69

-1865.06
7.79
ROA (%) -12.00
GHDX's ROA (%) is ranked higher than
61% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. GHDX: -12.00 )
GHDX' s 10-Year ROA (%) Range
Min: -91.5   Max: 6.18
Current: -12

-91.5
6.18
ROC (Joel Greenblatt) (%) -77.57
GHDX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. GHDX: -77.57 )
GHDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2388.09   Max: 74.51
Current: -77.57

-2388.09
74.51
Revenue Growth (%) 12.60
GHDX's Revenue Growth (%) is ranked higher than
86% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. GHDX: 12.60 )
GHDX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 136.8
Current: 12.6

0
136.8
» GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GHDX Guru Trades in Q3 2013

Chuck Royce 33,000 sh (unchged)
Jim Simons 37,800 sh (-77.37%)
» More
Q4 2013

GHDX Guru Trades in Q4 2013

Steven Cohen 14,221 sh (New)
Paul Tudor Jones 15,100 sh (New)
Jim Simons 52,901 sh (+39.95%)
Chuck Royce 33,000 sh (unchged)
» More
Q1 2014

GHDX Guru Trades in Q1 2014

Jim Simons 108,555 sh (+105.2%)
Chuck Royce 33,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

GHDX Guru Trades in Q2 2014

Chuck Royce 33,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Swensen 2013-03-31 Sold Out 2.8%$26.72 - $29.65 $ 33.6518%0
David Swensen 2012-12-31 New Buy2.8%$26.42 - $36.8 $ 33.6512%37861
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.33
GHDX's P/B is ranked lower than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. GHDX: 7.33 )
GHDX' s 10-Year P/B Range
Min: 3.3   Max: 14.23
Current: 7.33

3.3
14.23
P/S 3.83
GHDX's P/S is ranked higher than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. GHDX: 3.83 )
GHDX' s 10-Year P/S Range
Min: 2.17   Max: 20.45
Current: 3.83

2.17
20.45
EV-to-EBIT -48.15
GHDX's EV-to-EBIT is ranked lower than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: -48.15 )
GHDX' s 10-Year EV-to-EBIT Range
Min: -791   Max: 514.8
Current: -48.15

-791
514.8
Current Ratio 4.52
GHDX's Current Ratio is ranked higher than
84% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. GHDX: 4.52 )
GHDX' s 10-Year Current Ratio Range
Min: 3.54   Max: 15.83
Current: 4.52

3.54
15.83
Quick Ratio 4.52
GHDX's Quick Ratio is ranked higher than
87% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. GHDX: 4.52 )
GHDX' s 10-Year Quick Ratio Range
Min: 3.54   Max: 15.83
Current: 4.52

3.54
15.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.76
GHDX's Price/Net Cash is ranked higher than
80% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 14.76 )
GHDX' s 10-Year Price/Net Cash Range
Min: 3.64   Max: 22.82
Current: 14.76

3.64
22.82
Price/Net Current Asset Value 11.07
GHDX's Price/Net Current Asset Value is ranked higher than
79% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 11.07 )
GHDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.63   Max: 20.64
Current: 11.07

3.63
20.64
Price/Tangible Book 7.33
GHDX's Price/Tangible Book is ranked higher than
53% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. GHDX: 7.33 )
GHDX' s 10-Year Price/Tangible Book Range
Min: 3.3   Max: 11.72
Current: 7.33

3.3
11.72
Price/DCF (Projected) 5.15
GHDX's Price/DCF (Projected) is ranked higher than
68% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GHDX: 5.15 )
GHDX' s 10-Year Price/DCF (Projected) Range
Min: 2.61   Max: 38.47
Current: 5.15

2.61
38.47
Price/Median PS Value 0.88
GHDX's Price/Median PS Value is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. GHDX: 0.88 )
GHDX' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 3.62
Current: 0.88

0.52
3.62
Earnings Yield (Greenblatt) -2.10
GHDX's Earnings Yield (Greenblatt) is ranked lower than
127% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. GHDX: -2.10 )
GHDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 1.3
Current: -2.1

0.2
1.3
Forward Rate of Return (Yacktman) 0.76
GHDX's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. GHDX: 0.76 )
GHDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -42.1   Max: 77.8
Current: 0.76

-42.1
77.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:G7H.Germany
Genomic Health, Inc. was incorporated in Delaware in August 2000. The Company engages in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer.
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Should Genomic Health (GHDX) Be in Your Portfolio Now? Oct 15 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as... Sep 29 2014
Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent... Sep 26 2014
Genomic Health Upbeat on Strong International Performance Sep 25 2014
New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your... Sep 24 2014
Genomic Health Reveals Positive Oncotype DX Test Results Sep 15 2014
Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics Sep 12 2014
Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical... Sep 09 2014
GENOMIC HEALTH INC Financials Aug 15 2014
Genomic Health Raised to Buy on Better-than-Expected Q2 Aug 14 2014
Genomic Health Q2 Loss Narrower than Expected, Shares Up Aug 11 2014
GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference Aug 08 2014
GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress Aug 07 2014
Q2 2014 GENOMIC HEALTH INC Earnings Release - After Market Close Aug 07 2014
Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study... Aug 06 2014
Is a Surprise Coming for Genomic Health (GHDX) This Earnings Season? Aug 06 2014
Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on... Jul 31 2014
3 Health Care Stocks Primed For Big Moves Jul 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK